Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?

Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after shares moved sharply higher, helped by the late stage failure of a competing ATTR cardiomyopathy therapy from AstraZeneca and Ionis Pharmaceuticals, as well as recent collaboration updates.

See our latest analysis for Alnylam Pharmaceuticals.

Even after the recent surge following competitor trial setbacks and collaboration news, Alnylam Pharmaceuticals’ 1-day share price return declined 4.49%, capping a year to date share price...